Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC

Foresite Capital Management V LLC lifted its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 17.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 477,078 shares of the company’s stock after buying an additional 70,426 shares during the quarter. Lyell Immunopharma accounts for approximately 7.1% of Foresite Capital Management V LLC’s holdings, making the stock its 5th largest holding. Foresite Capital Management V LLC owned about 2.25% of Lyell Immunopharma worth $7,748,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. ARCH Venture Management LLC boosted its holdings in Lyell Immunopharma by 51.5% in the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after acquiring an additional 938,438 shares during the period. Two Sigma Investments LP raised its stake in shares of Lyell Immunopharma by 107.0% during the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after purchasing an additional 10,768 shares during the period. Takeda Pharmaceutical Co. Ltd. lifted its position in shares of Lyell Immunopharma by 33.3% during the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company’s stock worth $891,000 after purchasing an additional 13,722 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the period. Finally, Clarius Group LLC boosted its stake in shares of Lyell Immunopharma by 4.3% in the third quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock valued at $324,000 after purchasing an additional 820 shares during the period. 66.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, CEO Lynn Seely sold 7,455 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the transaction, the chief executive officer directly owned 74,266 shares of the company’s stock, valued at $1,737,081.74. This trade represents a 9.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary K. Lee sold 1,671 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $39,084.69. Following the completion of the sale, the insider directly owned 16,938 shares of the company’s stock, valued at $396,179.82. The trade was a 8.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 11,310 shares of company stock worth $264,285 in the last ninety days. 22.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently issued reports on LYEL. Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They set a “market outperform” rating and a $34.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. Finally, HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their target price for the company from $20.00 to $45.00 in a research note on Tuesday, December 9th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $39.50.

Lyell Immunopharma Stock Down 14.2%

Shares of LYEL opened at $21.25 on Monday. The firm has a market cap of $451.44 million, a price-to-earnings ratio of -1.30 and a beta of -0.14. The business’s 50 day moving average is $24.13 and its two-hundred day moving average is $21.61. Lyell Immunopharma, Inc. has a 52-week low of $7.65 and a 52-week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Thursday, March 12th. The company reported ($7.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($5.53). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Lyell Immunopharma had a negative return on equity of 90.52% and a negative net margin of 762,355.56%. On average, equities analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.